Fatma Zehra Kadayıfçı1,2, Makbule Gezmen Karadağ1. 1. Department of Nutrition and Dietetic, Gazi University, Ankara, Turkey. 2. Department of Health Sciences, California Baptist University, Riverside, California, USA.
Abstract
OBJECTIVE: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS). METHODS: Serum endocan levels were analyzed in 42 patients with AS under anti-TNF-alpha usage. Control group consisted of 37 patients with AS who are not receiving anti-TNF drugs. Endocan is analyzed using ESM-1 ELISA kits. The blood glucose and lipid measurements of patients were also assessed. RESULTS: There was no significant change in serum endocan levels among groups. The total cholesterol, triglyceride, and LDL-C levels were higher in patients receiving anti-TNF-alpha; however, differences were not significant. There was no significant correlation between serum endocan levels and blood lipid measurements. CONCLUSION: Anti-TNF-alpha treatment does not affect serum endocan levels in patients with AS. This research has been first to evaluate the relationship between serum endocan and anti-TNF-alpha therapy in AS. Future studies are necessary to verify the exact role of anti-TNF-alpha therapy on serum endocan levels in patients with AS.
OBJECTIVE: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS). METHODS: Serum endocan levels were analyzed in 42 patients with AS under anti-TNF-alpha usage. Control group consisted of 37 patients with AS who are not receiving anti-TNF drugs. Endocan is analyzed using ESM-1 ELISA kits. The blood glucose and lipid measurements of patients were also assessed. RESULTS: There was no significant change in serum endocan levels among groups. The total cholesterol, triglyceride, and LDL-C levels were higher in patients receiving anti-TNF-alpha; however, differences were not significant. There was no significant correlation between serum endocan levels and blood lipid measurements. CONCLUSION: Anti-TNF-alpha treatment does not affect serum endocan levels in patients with AS. This research has been first to evaluate the relationship between serum endocan and anti-TNF-alpha therapy in AS. Future studies are necessary to verify the exact role of anti-TNF-alpha therapy on serum endocan levels in patients with AS.
Authors: D Bechard; V Meignin; A Scherpereel; S Oudin; G Kervoaze; P Bertheau; A Janin; A Tonnel; P Lassalle Journal: J Vasc Res Date: 2000 Sep-Oct Impact factor: 1.934
Authors: Veysel Ozalper; Muammer Kara; Alpaslan Tanoglu; Ibrahim Cetındaglı; Coskun Ozturker; Yusuf Hancerlı; Serdar Hıra; Kemal Kara; Yavuz Beyazıt; Yusuf Yazgan Journal: Clin Rheumatol Date: 2017-01-10 Impact factor: 2.980
Authors: Filip Roudnicky; Cedric Poyet; Peter Wild; Sarah Krampitz; Fabrizia Negrini; Reto Huggenberger; Anja Rogler; Robert Stöhr; Arndt Hartmann; Maurizio Provenzano; Vivianne I Otto; Michael Detmar Journal: Cancer Res Date: 2012-12-14 Impact factor: 12.701
Authors: Mariusz Korkosz; Jerzy Gąsowski; Andrzej Surdacki; Piotr Leszczyński; Katarzyna Pawlak-Buś; Sławomir Jeka; Maciej Siedlar; Tomasz Grodzicki Journal: Pharmacol Rep Date: 2013 Impact factor: 3.024
Authors: Livia Victorino de Souza; Vanessa Oliveira; Aline Oliveira Laurindo; DelmaRegına Gomes Huarachı; Paulo Cesar Koch Nogueira; Luciana de Santis Feltran; José Osmar Medina-Pestana; Maria do Carmo Franco Journal: Int J Nephrol Date: 2016-12-19